Basilea infectious, dermatology news
Basilea will reduce its R&D headcount by 30 and add 100 employees to support the launch and commercialization of Toctino alitretinoin and Zeftera/ Zevtera ceftobiprole. Toctino is marketed to treat severe chronic hand eczema unresponsive to topical corticosteroids in the U.K., Denmark and Germany, and is approved in Finland and France. The vitamin A derived 9-cis retinoic acid also is under review in Canada and Switzerland and in an ongoing U.S. Phase III trial to treat severe chronic hand eczema.
Ceftobiprole is marketed in Canada as Zeftera and in Switzerland as Zevtera, and is under EMEA review treat complicated skin and soft tissue infections (cSSTIs). In December, FDA issued a complete response letter for an NDA from partner Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) for the broad spectrum anti-MRSA cephalosporin antibiotic to treat complicated skin and skin structure infections (cSSSIs), including diabetic foot infections (see BioCentury Dec. 8, 2008). ...